

INVESTMENT

- Total demand for capital to attain profitability: \$15M
- Previous cash: \$2.6M
- Discount for large and/or early investors
- Target ROI 25x (forward-looking statement)

WE HAVE BOTH


- Product to license
- Manufacturing technology

With the current round of investment, we will:

- Receive a conditional market authorization with the USDA*
- Establish a USDA-certified plasmid manufacturing facility (today, there is a shortage of such facilities in the USA and EU)
- Attain profitability within 4 years


* USDA grants license to a product manufacturer, not an IP holder. A manufacturer must be a USDA-licensed facility. To become a USDA-licensed facility, one must have a product.

CANCER IS THE LEADING CAUSE OF DEATH IN PETS*



*The Veterinary Cancer Society

GROWTH IN VETERINARY CANCER MARKET



Shortage of good products severely limits the market size. CureLab's products will drive market growth.

- ElenaVet™ is patented in 20+ countries
- Unique mechanism of action
- Proof of concept in dogs and cats

- Experienced management team
- Clear regulatory path via USDA
- Unmet and growing market need

PET CARE IS A GROWTH MARKET

US pet care market valued at \$281B by 2023 (the Kiplinger Report). Global CAGR 6.6% (Infinium Global Research)

- 89.7M dogs and 95.6M cats in US (growing)
- Continued humanization of pets makes caring for them more important to pet owners
- ElenaVet will resonate with pet owners both on pet care and price

Lead Product, ElenaVet™

Effective, affordable, easy to administer.

- Circular supercoiled DNA, plasmid, carrying a gene for p62/SQSTM1
- Stimulates anti-cancer immune response and changes tumor microenvironment
- Reduces systemic chronic inflammation
- Safety shown in animal and human studies
- Highly technological and stable
- Intramuscular administration

Cost of Care

- 1 round of chemotherapy \$3-\$5K
 - 1 round of ElenaVet \$3K*
- *CureLab wholesale price \$2K; Expected COGS <20%

Timeline

- Incorporated: November 2020
- Conditional USDA licensure: 18-24 months
- Profitability: 36-42 months

Future Non-Cancer Applications

Diseases with common cause, chronic inflammation:

- Osteoarthritis
- IBD
- Chronic dermatological conditions



NO DOG OR CAT SHOULD DIE OF BREAST CANCER

- Published: 10 out of 11 dogs with mammary cancer positively responded to ElenaVet and showed no relapse for years
- Unpublished: cats with breast cancer and dogs with melanoma respond to ElenaVet

Our immediate goal is to protect pets from cancer. Breast cancer and oral melanoma are our initial targets.